Academic Journal
Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.
| Title: | Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry. |
|---|---|
| Authors: | Rob, Filip1 (AUTHOR) filip.rob@gmail.com, Gkalpakiotis, Spyridon2 (AUTHOR), Kojanová, Martina3 (AUTHOR), Vantuchová, Yvetta4 (AUTHOR), Čelakovská, Jarmila5 (AUTHOR), Horažďovský, Jiří6 (AUTHOR), Baláž, Monika7,8 (AUTHOR), Nečas, Miroslav9 (AUTHOR), Stuchlík, David10 (AUTHOR), Cetkovská, Petra11 (AUTHOR), Hrazdírová, Kateřina12 (AUTHOR), Machovcová, Alena13 (AUTHOR), Pinková, Blanka14 (AUTHOR), Třešňák Hercogová, Jana15 (AUTHOR) |
| Source: | Journal of the European Academy of Dermatology & Venereology. Dec2025, Vol. 39 Issue 12, pe1056-e1059. 4p. |
| Subject Terms: | *Atopic dermatitis, *Interleukin-13, *Cohort analysis, *Adverse health care events, *Biotherapy, *Treatment effectiveness |
| Abstract: | The article focuses on the effectiveness and safety of lebrikizumab, an anti-interleukin-13 antibody, for treating moderate-to-severe atopic dermatitis (AD) based on a 24-week analysis from the Czech BIOREP registry. The study involved 181 patients, with 63.7% achieving an Eczema Area and Severity Index (EASI)-75 response after 16 weeks, and a notable difference in response rates between treatment-naïve patients and those who previously failed dupilumab therapy. Adverse events were reported in 13.8% of patients, primarily conjunctivitis, but none were serious. The findings suggest that lebrikizumab is effective and safe in real-world settings, although prior treatment failures may impact efficacy. [Extracted from the article] |
| Database: | Academic Search Index |
Be the first to leave a comment!